Robust methods for missing covariates in longitudinal studies with application to biomarker research in Parkinson’s disease dementia
Objective: We propose a nonparametric method for handling different types of missing covariates in longitudinal studies. We show that the proposed method outperforms multiple standard…A Report from Japan on Initial Experiences with Adaptive Deep Brain Stimulation Therapy for Patients with Advanced Parkinson’s Disease
Objective: Here we present our initial experience with deep brain stimulation therapy (DBS) for Parkinson's disease (PD) using the closed-loop system. Background: Although DBS is…Microglial activation facilitates alpha synuclein propagation and neurodegeneration in αSyn preformed fibrils (PFF)-injected PD mouse model
Objective: To evaluate whether microglial activation aggravates synucleinopathy progression in Parkinson's disease (PD) mouse model. Background: Alpha-synuclein (αSyn) accumulation underlay the main pathological process of…Co-contractions as a Biomarker for DBS Efficacy in Dystonia
Objective: Deep brain stimulation of the globus pallidus interna (GPi-DBS) is a treatment option for medication-refractory dystonia. However, the clinical outcome after DBS-GPi is variable,…APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation
Objective: There were accumulating evidence proving that rifampicin could protect neurons from apoptosis in Parkinson's disease in-vitro model by regulating SUMO modification of α-synuclein. However,…Delayed Osmotic Demyelination Syndrome- An Evolving Spectrum
Objective: To report a case of osmotic demyelination syndrome (ODS) with continuing clinical and radiological worsening beyond its previously established temporal course. Background: ODS is…Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database
Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…Distribution of rapid eye movement (REM) sleep without atonia (RWA) across the REM cycles.
Objective: This study aimed to evaluate whether rapid eye movement )REM( sleep without atonia )RWA( is similar throughout multiple REM cycles during one night. Background:…Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling
Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.